Inve India ▾

Alivus Life share price & results

Alivus Life· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

API manufacturer (ex-Glenmark Life Sciences) making generic and complex active pharmaceutical ingredients plus CDMO services.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue640 ₹ crore+6.3% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin33.0 %+4.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit160 ₹ crore+31.1% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity20.22 %−0.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin10.15 %+0.6 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)7.87 %+2.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

3 of 8 judged targets kept · 13 open · verdicts reflect calls analysed to Q1 FY27.

Alivus Life management guidance track record on Inve: 21 targets tracked across analysed earnings calls (3 achieved, 5 missed, 13 open).

TargetOriginal wordingSaidLatest callVerdict
FY25 Gross Margin52-55%
Call transcript, Q2 FY25 · 25 Oct 2024		Q2 FY25Q1 FY27:Promise concluded in a prior period.
Call transcript, Q1 FY27 · 31 Jul 2026		Achieved
FY25 Revenue Growthhigh single digit (revised down from mid-teens)
Call transcript, Q2 FY25 · 25 Oct 2024		Q2 FY25Q1 FY27:Promise concluded in a prior period.
Call transcript, Q1 FY27 · 31 Jul 2026		Missed
Solapur Operational StartEnd of Q3 FY26
Call transcript, Q2 FY25 · 25 Oct 2024		Q2 FY25Q1 FY27:Timeline delayed again, from Q2 FY27 to 'early Q3 FY27'. Management cites a calibrated approach to avoid under-absorption.
Call transcript, Q1 FY27 · 31 Jul 2026		Delayed

Source: Inve Guidance Tracker for Alivus Life · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of Alivus Life's 21 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 18 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,343.6 +6.47% · +₹81.6

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +45.4% 1Y

₹1.0k₹1.2k₹1.4kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q3 FY26 — 22 Jan 2026Q4 FY26 — 15 May 2026Q1 FY27 — 31 Jul 2026

1Y: ₹924.15 on 24 Oct 2025 → ₹1,343.6. High ₹1,443.7 (1 Sept 2026), low ₹860.05 (8 Dec 2025).

Previous close
₹1,262
Market cap
₹15.5k Cr
52-week range
₹860.05 – ₹1,443.7
One year
+46.16%
Price to earnings (TTM to Jun 2026)
24.91×
Return on equity (TTM to Jun 2026)
20.22%

Overview

Symbol
NSE:ALIVUS
Exchange
NSE
Currency
INR

What Alivus Life does

Based on the company's own presentations, annual report and earnings calls.

Alivus Life Sciences (formerly Glenmark Life Sciences, spun out of Glenmark Pharmaceuticals and now majority-owned by Nirma Limited) manufactures active pharmaceutical ingredients (APIs) sold to generic-drug makers worldwide, alongside a Contract Development and Manufacturing Organisation (CDMO) business that develops and manufactures APIs for third-party pharma customers. It runs four API manufacturing plants in Gujarat and Maharashtra and supplies molecules across therapy areas such as cardiovascular, CNS, diabetes, oncology, urology and pain management to customers in regulated and emerging markets. A fifth, greenfield plant is under construction at Solapur, Maharashtra, and the company maintains an in-house R&D and regulatory-filing base that underpins its DMF/CEP registrations across major global markets.

Segments

  • Generic API
  • CDMO (Contract Development & Manufacturing Organisation)
Manufacturing facilities
4 (Ankleshwar & Dahej in Gujarat; Mohol & Kurkumbh in Maharashtra), plus a greenfield plant under construction at Solapur
Total installed reactor capacity
1,424 KL
DMF/CEP filings (cumulative)
611 filings across US, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia
Customer base
~900 customers globally (FY26); 700+ customers across 75+ countries as of FY25
Employees
2,203, including 163 women employees
High-potency API (HPAPI) pipeline
28 products in development grid; 12 validated, 7 in advanced stages
Founded 2011Headquarters Mumbai, Maharashtra (corporate office); Solapur, Maharashtra (registered office)Employees 2,203 (2025-03-31) Company website

How the price took the results

close before → close after

Q1 FY27
+5.9%
31 Jul
Q4 FY26
−1.8%
15 May
Q3 FY26
+0.0%
22 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Alivus Life

Free account: one company. Everything above stays public.

Write why you follow Alivus Life and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Alivus Life

Guides on how to read this kind of business and the numbers that matter.